Recent interest in the inhibition of the immune checkpoint proteins programmed death ligand-1 (PDL1) and its receptor programmed cell death protein 1 (PD1) has resulted in the approval of these drugs for the treatment of numerous cancer types [126]. Here, CD274 is linked to cancer.